Journal: Biosensors & bioelectronics

Article Title: Microarray method to monitor 40 intestinal bacterial species in the study of azo dye reduction

doi: 10.1016/j.bios.2004.04.011

Figure Lengend Snippet: Bacteria and the probe numbers in the microarray

Article Snippet: Anaerobic bacteria were cultured at 35 °C in either prereduced anaerobically sterilized (PRAS) Brain Heart Infusion (BIH) broth supplemented with vitamin K and hemin (Remel, Lenexa, KS, USA), inoculated under an oxygen-free cannula using 85% nitrogen, 10% hydrogen and 5% carbon dioxide, or on PRAS brucella blood agar plates supplemented with vitamin K and hemin (Remel). table ft1 table-wrap mode="anchored" t5 caption a7 Number Bacterial species and strain Probe number 1 B. thetaiotaomicron ATCC 29148 1, 2, 3 2 B. vulgatus ATCC 8482 4, 5, 6 3 B. fragilis ATCC 23745 7, 8, 9 4 B. distasonis ATCC 8503 10, 11, 12 5 C. clostridioforme ATCC 29084 13, 14, 15 6 C. leptum ATCC 29065 16, 17, 18 7 F. prausnitzii ATCC 27768 19, 20, 21 8 P. productus ATCC 27340 22, 23, 24 9 R. obeum ATCC 29174 25, 26, 27 10 R. bromii ATCC 27255 28, 29, 30 11 R. callidus ATCC 27760 31, 32, 33 12 R. albus ATCC 27210 34, 35, 36 13 B. longum ATCC 15707 37, 38, 39 14 B. adolescentis ATCC 15703 40, 41, 42 15 B. infantis ATCC 15697 43, 44, 45 16 E. biforme ATCC 27806 46, 47, 48 17 E. aerofaciens ATCC 25986 49, 50, 51 18 L. acidophilus ATCC 4356 52, 53, 54 19 E. coli ATCC 25922 55, 56, 57 20 E. faecium ATCC 19434 58, 59, 60 21 B. uniformis ATCC 8492 61, 62, 63 22 B. ovatus ATCC 8483 64, 65, 66 23 B. caccae ATCC 43185 67, 68, 69 24 C. perfringens ATCC 13124 70, 71, 72 25 C. butyricum ATCC 19398 73, 74, 75 26 C. ramosum ATCC 25582 76, 77, 78 27 C. difficile ATCC 9689 79, 80, 81 28 C. indolis ATCC 25771 82, 83, 84 29 F. russii ATCC 25533 85, 86, 87 30 F. nucleatum ATCC 25586 88, 89, 90 31 B. catenulatum ATCC 27539 91, 92, 93 32 B. angulatum ATCC 27535 94, 95, 96 33 E. rectale ATCC 33656 97, 98, 99 34 E. eligens ATCC 27750 100, 101, 102 35 E. limosum ATCC 8486 103, 104, 105 36 E. lentum ATCC 25553 106, 107, 108 37 L. fermentum ATCC 9338 109, 110, 111 38 E. faecalis ATCC 27274 112, 113, 114 39 P. magnus ATCC 14955 115, 116, 117 40 R. gnavus ATCC 291492 118, 119, 120 Open in a separate window Bacteria and the probe numbers in the microarray 2.2.

Techniques: Bacteria

Journal: Biosensors & bioelectronics

Article Title: Microarray method to monitor 40 intestinal bacterial species in the study of azo dye reduction

doi: 10.1016/j.bios.2004.04.011

Figure Lengend Snippet: Microarray test results read from

Article Snippet: Anaerobic bacteria were cultured at 35 °C in either prereduced anaerobically sterilized (PRAS) Brain Heart Infusion (BIH) broth supplemented with vitamin K and hemin (Remel, Lenexa, KS, USA), inoculated under an oxygen-free cannula using 85% nitrogen, 10% hydrogen and 5% carbon dioxide, or on PRAS brucella blood agar plates supplemented with vitamin K and hemin (Remel). table ft1 table-wrap mode="anchored" t5 caption a7 Number Bacterial species and strain Probe number 1 B. thetaiotaomicron ATCC 29148 1, 2, 3 2 B. vulgatus ATCC 8482 4, 5, 6 3 B. fragilis ATCC 23745 7, 8, 9 4 B. distasonis ATCC 8503 10, 11, 12 5 C. clostridioforme ATCC 29084 13, 14, 15 6 C. leptum ATCC 29065 16, 17, 18 7 F. prausnitzii ATCC 27768 19, 20, 21 8 P. productus ATCC 27340 22, 23, 24 9 R. obeum ATCC 29174 25, 26, 27 10 R. bromii ATCC 27255 28, 29, 30 11 R. callidus ATCC 27760 31, 32, 33 12 R. albus ATCC 27210 34, 35, 36 13 B. longum ATCC 15707 37, 38, 39 14 B. adolescentis ATCC 15703 40, 41, 42 15 B. infantis ATCC 15697 43, 44, 45 16 E. biforme ATCC 27806 46, 47, 48 17 E. aerofaciens ATCC 25986 49, 50, 51 18 L. acidophilus ATCC 4356 52, 53, 54 19 E. coli ATCC 25922 55, 56, 57 20 E. faecium ATCC 19434 58, 59, 60 21 B. uniformis ATCC 8492 61, 62, 63 22 B. ovatus ATCC 8483 64, 65, 66 23 B. caccae ATCC 43185 67, 68, 69 24 C. perfringens ATCC 13124 70, 71, 72 25 C. butyricum ATCC 19398 73, 74, 75 26 C. ramosum ATCC 25582 76, 77, 78 27 C. difficile ATCC 9689 79, 80, 81 28 C. indolis ATCC 25771 82, 83, 84 29 F. russii ATCC 25533 85, 86, 87 30 F. nucleatum ATCC 25586 88, 89, 90 31 B. catenulatum ATCC 27539 91, 92, 93 32 B. angulatum ATCC 27535 94, 95, 96 33 E. rectale ATCC 33656 97, 98, 99 34 E. eligens ATCC 27750 100, 101, 102 35 E. limosum ATCC 8486 103, 104, 105 36 E. lentum ATCC 25553 106, 107, 108 37 L. fermentum ATCC 9338 109, 110, 111 38 E. faecalis ATCC 27274 112, 113, 114 39 P. magnus ATCC 14955 115, 116, 117 40 R. gnavus ATCC 291492 118, 119, 120 Open in a separate window Bacteria and the probe numbers in the microarray 2.2.

Techniques: Microarray

Journal: Immunity

Article Title: CRISPR screens unveil nutrient-dependent lysosomal and mitochondrial nodes impacting intestinal tissue-resident memory CD8 + T cell formation

doi: 10.1016/j.immuni.2024.09.013

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Purified naive OT-I, P14, or YopE-I cells were activated for 20 h with 5 μg/ml plate-bound anti-CD3 (2C11, Bio X Cell) and 5 μg/ml plate-bound anti-CD28 (37.51, Bio X Cell) in complete Click’s medium (catalog #9195, Irvine Scientific) containing 10% fetal bovine serum (FBS; R&D Systems), 1× penicillin–streptomycin–L-glutamine (catalog #15140122, Thermo Fisher Scientific), and 55 μM β-mercaptoethanol.

Techniques: Purification, Virus, Expressing, Mutagenesis, Recombinant, Electron Microscopy, Control, Modification, Plasmid Preparation, Cell Isolation, Transfection, Sample Prep, Reverse Transcription, SYBR Green Assay, Microarray, RNA Sequencing Assay, Knock-In, Sequencing, Software, Flow Cytometry, Microscopy, Real-time Polymerase Chain Reaction

Journal: Frontiers in Immunology

Article Title: Guanabenz Prevents d -Galactosamine/Lipopolysaccharide-Induced Liver Damage and Mortality

doi: 10.3389/fimmu.2017.00679

Figure Lengend Snippet: Guanabenz (GBZ) immunomodulatory effect on TLR4 signaling. (A) GM-CSF-derived dendritic cells (DCs) were stimulated for 8 h with Proteus mirabilis (0.1 MOI), in the presence or absence of GBZ (50 µM). Gene expression was established by Affymetrix microarray analysis and compared with the ingenuity pathway analysis (IPA) Ingenuity Pathway software. Venn diagram was used to separate DEGs in three subsets. Tables contain selected DEGs for each subset and displaying the highest difference in expression level compared to control groups. Major upstream regulators identified by IPA are presented for each subset or group. (B) GM-CSF-derived DCs were treated for 6 h with 100 ng/ml lipopolysaccharide (LPS) 055:B5, in the presence or absence of GBZ (50 µM). Protein lysates were blotted for P-eIF2α and total eIF2α. The ratio, calculated in three independent experiments, was plotted. (C) On the same samples, the level of interleukin-10 (IL-10) transcription and secretion was measured by qPCR ( n = 3) and ELISA ( n = 4) (D) . GM-CSF-derived DCs were treated for 8 h with P. mirabilis (0.1 MOI) or 10 µg/ml of poly I:C, with or without GBZ (50 µM). The secretion of IL-12 ( n = 3) and IL-6 ( n = 4) was measured by ELISA. Statistical significance was assigned using one-way ANOVA test followed by Tukey range test to assess the significance among pairs of conditions (* p < 0.05; *** p < 0.001; **** p < 0.0001).

Article Snippet: Rabbit polyclonal antibody against p-eIF2α (Ser51) was from Abcam.

Techniques: Derivative Assay, Gene Expression, Microarray, Software, Expressing, Control, Enzyme-linked Immunosorbent Assay

Journal: iScience

Article Title: Neuropilin-1 cooperates with PD-1 in CD8 + T cells predicting outcomes in melanoma patients treated with anti-PD1

doi: 10.1016/j.isci.2022.104353

Figure Lengend Snippet: NRP1 is expressed in activated CD8 + T cells and controls their antitumoral function in mice (A) NRP1 expression and cell trace intensity analyzed by flow cytometry in OT1 murine CD8 + T cells activated during 24, 48, 72, and 96 h with OVA 257 peptide pulsed on dendritic cells (SIINFEKL, 10 −9 mg/mL). Data are representative of 5 independent experiments. (B) Flow cytometry analysis of NRP1 expression in OT1 murine CD8 + T cells, 72 h after activation with OVA peptide (SIINFEKL, 10 −9 mg/mL). Expression is shown according to different effector CD8 + T cell / antigen-presenting cell (DC) ratios (E/A ratio: 1/1, 2/1, 4/1, and 8/1). p value (p = 0.0006) was determined by one-way ANOVA. Data are representative of 2 independent experiments. Expression was assessed by flow cytometry and data are presented as the mean ± SEM of percentage of NRP1 on CD8 + T cells (c) Expression of NRP1 in CD8 + T cells from B6 mice, after intramuscular immunization with AAV-OVA vector. Expression was assessed by flow cytometry and data are presented as the mean ± SEM of percentage of NRP1 on iTAg Tetramer/PE - H-2 Kb OVA, at day 7, 14, 21, 28, and 35 after immunization. Data are representative of 5 independent experiments. (D) NRP1 expression profiles in H2-Db GP33-specific CD8 + T cells according to in vivo infection in mice with LCMV Armstrong (n = 16), LCMV clone 13 (n = 16), or naïve CD44 low CD8 + T cells from controls (n = 4) at days 6, 8, 15, and 30. Raw transcriptomic data were from Doering et al. (2012) microarray experiments [32]. Data are presented as the mean ± SEM p value was determined by two-way ANOVA(p = 0.0008). (E) Flow cytometry analysis of NRP1 expression (blue line curve) on iTAg Tetramer/PE - H-2 Kb OVA CD8 + TILs collected from C57BL/6 mice bearing a B16-OVA tumor at day 14 post-immunization with ovalbumin and poly-IC. Data are representative of 3 independent experiments. (F) Flow cytometry analysis of NRP1 and PD1 expression in OT1 CD8 + T cells activated with OVA 257 peptide (SIINFEKL, 10 −9 M) at 24, 48, 72, and 96 h post-activation. Data are representative of 3 independent experiments. (H) Mice were pre-immunized (immunized) or not pre-immunized (control) with ovalbumin and poly-IC. B16-OVA tumor volume was assessed at day 0, 8, 11, 14, and 18 post-immunization in CD8Nrp1KO (KO) and control C8Cre (WT) mice. Data are presented as mean ± SEM. p values were determined by using student t- test ∗∗∗p < 0.001, ∗p < 0.05. Data are representative of 3 independent experiments. (G) CD8Nrp1KO (KO) and control (WT) mice were injected in the right flank with 1 × 10 5 TC1 lung tumor cells subcutaneously. Data are presented as mean ± SEM p values was determined by using student t- test ∗∗p < 0.01, ∗p < 0.05. Data are representative of 3 independent experiments (I) CD8Nrp1KO (KO) and control (WT) mice were pre-immunized with ovalbumin and poly-IC. Tumor volume was assessed 21 days after immunization. Data are presented as mean ± SEM p values was determined by using student t- test (p = 0.0012). Data are representative of 3 independent experiments. (J) Number of CD8 + TILs per fields with highest CD8 + T cells infiltration from CD8Nrp1KO mice (KO) or controls (WT) assessed by confocal microscopy at day 21 post immunization with ovalbumin and poly-IC. Data are presented as mean ± SEM. p values (p < 0.0001) was determined by using student t- test. Data are representative of 3 tumors per group. (K) Percentages of Tetramer/PE - H-2 Kb OVA CD8 + TILs in B16-OVA tumors of four different mice group assessed at day 14 post-immunization by flow cytometry from CD8Nrp1KO (KO) and control (WT) mice immunized or not immunized (control) with ovalbumin and poly-IC. Data are presented as the mean percentage of CD8 + TILs Tetramer positive ± SEM. p values were determined by using student T test ∗∗p < 0.01, ∗p < 0.05. Data are representative of 2 independent experiments. (L) Ex vivo TILs proliferation was analyzed by flow cytometry 72 h post-activation with anti-CD3 and anti-CD28. TILs were collected from B16-OVA tumors at day 21 post-immunization from 3 mice. Data are presented as the mean percentage of divided CD8 + T cells ± SEM. p values was determined by using student t- test ∗∗∗p < 0.001. Data are representative of 2 independent experiments.

Article Snippet: anti-mouse CD28 (37.51) , BioXcell , Cat# BE0015-1, RRID: AB_1107624.

Techniques: Expressing, Flow Cytometry, Activation Assay, Plasmid Preparation, In Vivo, Infection, Microarray, Control, Injection, Confocal Microscopy, Ex Vivo

Journal: iScience

Article Title: Neuropilin-1 cooperates with PD-1 in CD8 + T cells predicting outcomes in melanoma patients treated with anti-PD1

doi: 10.1016/j.isci.2022.104353

Figure Lengend Snippet: NRP1 modulates PD1 activity at the synapse between CD8 + T cells and tumor cells (A) Illustrative image of phalloidin (yellow), CD8 (pink), CFP from EL4 (purple), and NRP1 (red) labeling in the synapse model between activated OT1 CD8 + T cells and EL4-CFP tumor cells bearing OVA 257 (SIINFEKL), observed by ImageStream. The synapse is the high phalloidin labeling zone. Bright field image is in white (scale bar = 7μm). Data are representative of 4 independent experiments from 2 synapse models. (B) Quantification by ImageStream of NRP1 expression (mean pixel intensity/MPI) in an allogeneic synapse model between activated CD8 + T cells and cell tracer violet labeled A20 cells. NRP1 expression was analyzed in activated CD8 + T cells at the synapse junction (high phalloidin labeling zone). Data are presented as the mean MPI ± SEM. p value (p < 0.0001) was determined by Wilcoxon matched pairs test. Data are representative of 4 independent experiments from 2 synapse models. (C) Illustrative image of phalloidin (yellow), phospho-ZAP70 (green), CD8 (red), cell tracer violet labeled A20 tumor cells (purple), and NRP1 (white) between activated NRP1 high or NRP1 low CD8 + T cells and cell tracer violet labeled A20 tumor cells observed by ImageStream. The synapse is the high phalloidin labeling zone. Bright field image is in white (scale bar = 7μm). Data are representative of 2 independent experiments. (D) Quantification by Imagestream of phospho-ZAP70 amounts (mean pixel intensity/MPI) in the synapse junction (high phalloidin labeling zone) between activated NRP1 high or NRP1 low CD8 + T cells and cell tracer violet labeled A20 tumor cells. Data are presented as mean MPI ± SEM. p value (p < 0.0001) was determined by Mann Whitney test. Data are representative of 2 independent experiments. (E) Left panel: CD8 (green) NRP1 (red), PD1 (blue), and NRP1/PD1 merge (purple) expression observed by confocal microscopy in CD8 + TILs from control mice (WT) at day 21 post-activation (x63 oil objective, scale bar = 10 μm). Data are representative of 3 tumors. Right panel: Colocalization of NRP1 and PD1 was assessed by the calculation of Pearson coefficient. Data from 10 CD8 + TILs analyzed are presented as mean ± SEM. (F) Phospho-ZAP70 signal according to its localization within the synapse between the CD8 + T cells and the tumor cells. Illustrative image of phalloidin (yellow), phospho-ZAP70 (green), CD8 (red), and Cell Tracer (A20 cells, purple) labeling in the synapse model between activated CD8 + T cells from CD8Nrp1KO mice (KO) or controls (WT) and allogeneic A20 tumor cells, by ImageStream. Bright field image is in white (scale bar = 7μm). Data are representative of 2 independent experiments. (G) Phospho-ZAP70 signal according to its localization within the synapse between the CD8 + T cells and the tumor cells. Quantification by Image stream of phospho-ZAP70 amounts (mean pixel intensity/MPI) in the synapse junction (high phalloidin labeling zone) between activated CD8 + T cells from CD8Nrp1KO mice (KO) or control mice (WT), and cell tracer violet labeled A20 tumor cells. Data are presented as mean MPI ± SEM. p value (p < 0.0001) was determined by Mann Whitney test. Data are representative of 2 independent experiments. (H) Proximity of NRP1 and PD1 proteins demonstrated by Duolink assay on in vitro activated CD8 + T cells from C57BL/6J mice. Upper panel: Left: Negative control experiments performed using anti-IRAP and anti-NRP1 antibodies (PLA-Duolink). Right: NRP1/PD1 complexes (anti-NRP1 and anti-PD1 antibodies with PLA-Duolink). The red spots indicate less than 40nm proximity between cellular-bound antibodies. Nuclei are stained with DAPI (blue). Images have been observed by confocal microscopy (x63 oil objective, scale bar = 10μm). Data are representative of 5 independent experiments. Lower panel: Comparison of number of PLA plots per cell. Data are presented as mean ± SEM. (I) NRP1 and PD1 interaction was demonstrated by CoIP experiments performed in splenocytes from C57BL/6J mice activated with anti-CD3 and anti-CD28 antibodies. NRP1 and PD1 immunoblot (IB) detection is shown in total lysate (TL) as control, in eluate from IgG Control (ctl) IP, and from NRP1 IP (N = 1 experiment). NRP1/PD1 Co-IP was also observed after PD1 IP (N = 2 experiment). Data are representative of 3 independent experiments. (J) Quantification by Imagestream of PD1 expression (MPI) in the synapse junction (high phalloidin labeling zone) between activated CD8 + T cells from CD8Nrp1KO mice (KO) or controls (WT), and allogeneic A20 tumor cells. Data are presented as mean MPI ± SEM. p value (p < 0.0001) was determined by Mann Whitney test. Data are representative of 2 independent experiments.

Article Snippet: anti-mouse CD28 (37.51) , BioXcell , Cat# BE0015-1, RRID: AB_1107624.

Techniques: Activity Assay, Labeling, Expressing, MANN-WHITNEY, Confocal Microscopy, Control, Activation Assay, In Vitro, Negative Control, Staining, Comparison, Western Blot, Co-Immunoprecipitation Assay

Journal: iScience

Article Title: Neuropilin-1 cooperates with PD-1 in CD8 + T cells predicting outcomes in melanoma patients treated with anti-PD1

doi: 10.1016/j.isci.2022.104353

Figure Lengend Snippet: Targeting both NRP1 and PD1 has a synergistic effect in human and mouse CD8 + T cells immune response (A) Flow cytometry analysis of NRP1 expression according to cell trace on human CD8 + T cells 96 h after activation with anti-CD3 and anti-CD28, or on nonactivated cells. Data are representative of 5 independent experiments. (B) Flow cytometry analysis of NRP1 and PD1 expression in human CD8 + T cells 96 h after in vitro activation with anti-CD3 and anti-CD28 or non-activated cells. Data are representative of 3 independent experiments. (C) Flow cytometry analysis of NRP1 and PD1 expression in CD8 + TILs. Data are representative of 3 independent experiments in human endometrial, kidney, and ovarian cancer. (D) Flow cytometry analysis of phospho-ZAP70 in PD1 + CD8 + TILs according to NRP1 expression. Data from one experiment in human endometrial cancer. (E) Flow cytometry analysis of percentage of divided CD8 + T cells from a patient bearing an NRP1 haploinsufficiency (patient) or from controls (N = 5), respective to SEB superantigen concentration (0, 1, 10, or 100 ng/mL), in the presence or not of anti-PD1 antibody. Activation was performed during 72 h. Data are presented as the mean ± SEM. Data representative of 1 experiment. (F) Flow cytometry analysis of CD25 expression in CD8 + T cells from a patient bearing an NRP1 haploinsufficiency (patient) or from controls (N = 5), respective to SEB superantigen concentration (0, 1, 10, or 100 ng/mL), in the presence or not of anti-PD1 antibody. Activation was performed during 72 h. Data are presented as the mean % of CD25 expression ± SEM. Data representative of 1 experiment. (G) NRP1/PD-1 complexes detection by Proximity-Ligation-Assay (PLA) technology on CD8 + TILs in human colon cancer. Left panel: Representative area of tumor tissue observed. Acquisition with NDPI view software. Middle panel: Tumor infiltrating NRP1 + PD1 + CD8 + T cells (pink): Merge of green CD8 staining (FITC) and orange NRP1/PD-1 spots (TRITC). Acquisition with NDPI view software: zoom in x20. Right panel: CD8 + NRP1/PD1 positive cell (Pink) and CD8 + NRP1/PD1 negative cells (green). Acquisition with NDPI view software: zoom in x40. Nuclei are stained with DAPI (blue). Images have been observed by confocal microscopy ×20 oil objective. Data are representative of 10 independent experiments. (H) CD8Nrp1KO (KO) and control (WT) mice were pre-immunized with ovalbumin and poly-IC and treated or not with anti-PD1 antibody in vivo . B16-OVA tumor volume was assessed until 35 days after immunization. Data are presented as the mean ± SEM and as Kaplan Meyer curve. p values were determined by two-way ANOVA test ∗∗∗p < 0.001 ∗∗p < 0.01. Data are representative of 5 experiments. (I) CD8Nrp1KO (KO) and control (WT) mice were pre-immunized with ovalbumin and poly-IC and treated or not with anti-PD1 antibody in vivo . Overall survival was assessed until 50 days after immunization. Data are presented as the mean ± SEM and as Kaplan Meyer curve. p values were determined by Log rank test ∗∗∗p < 0.001. Data are representative of 5 experiments. (J) Analysis of overall survival of patients with metastatic melanoma treated with anti-PD1, according to RNA NRP1 expression (low or high expression: groups have been determined according to ROC curve analysis) assessed in the tumor before anti-PD1 treatment. Data from transcriptomics analysis of metastatic melanoma tumors were available from Hugo et al. ( Hugo et al., 2016 ) Data are presented as Kaplan Meyer curve. p value (p = 0.040) was determined by Log-rank test (n = 25 patients). (K) Analysis of relapse free survival of patients with metastatic melanoma treated with anti-PD1 and reached at least a partial response, according to NRP1 expression (NRP1 -/low compared with NRP1 +/high ) in CD8 + TILs assessed by immunohistochemistry before starting therapy. Blind analysis has been performed to assess NRP1 expression. Data are presented as the Kaplan Meyer curve. p value (p = 0.042) was determined by Log-rank test (n = 15 patients).

Article Snippet: anti-mouse CD28 (37.51) , BioXcell , Cat# BE0015-1, RRID: AB_1107624.

Techniques: Flow Cytometry, Expressing, Activation Assay, In Vitro, Concentration Assay, Proximity Ligation Assay, Software, Staining, Confocal Microscopy, Control, In Vivo, Immunohistochemistry

Journal: iScience

Article Title: Neuropilin-1 cooperates with PD-1 in CD8 + T cells predicting outcomes in melanoma patients treated with anti-PD1

doi: 10.1016/j.isci.2022.104353

Figure Lengend Snippet:

Article Snippet: anti-mouse CD28 (37.51) , BioXcell , Cat# BE0015-1, RRID: AB_1107624.

Techniques: Affinity Purification, In Situ, Virus, Recombinant, Transfection, Membrane, Software

Journal: Cell Reports Medicine

Article Title: Discovery and Verification of Extracellular miRNA Biomarkers for Non-invasive Prediction of Pre-eclampsia in Asymptomatic Women

doi: 10.1016/j.xcrm.2020.100013

Figure Lengend Snippet: Previously Published Studies Reporting Extracellular miRNA Biomarkers for Prediction or Diagnosis of Pre-eclampsia

Article Snippet: Martinez-Fierro et al. Mexico , serum , miRNeasy Mini Kit (QIAGEN , TaqMan Low Density Array Human MicroRNA Card Set v2.0, focused on 51 C19MC miRNAs (Applied Biosystems) , 34 (16 PE, 18 control) , 12, 16, and/or 20 weeks, asymptomatic, longitudinal , –,–,–, p < 0.05 , hsa-miR-520c-3p (16 weeks); hsa-miR-512-3p, 518f-3p, 520d-3p (20 weeks) , .

Techniques: Biomarker Discovery, Isolation, Control, Clinical Proteomics, Microarray, TLDA Assay, Extraction

Journal: Cell Reports Medicine

Article Title: Discovery and Verification of Extracellular miRNA Biomarkers for Non-invasive Prediction of Pre-eclampsia in Asymptomatic Women

doi: 10.1016/j.xcrm.2020.100013

Figure Lengend Snippet:

Article Snippet: Martinez-Fierro et al. Mexico , serum , miRNeasy Mini Kit (QIAGEN , TaqMan Low Density Array Human MicroRNA Card Set v2.0, focused on 51 C19MC miRNAs (Applied Biosystems) , 34 (16 PE, 18 control) , 12, 16, and/or 20 weeks, asymptomatic, longitudinal , –,–,–, p < 0.05 , hsa-miR-520c-3p (16 weeks); hsa-miR-512-3p, 518f-3p, 520d-3p (20 weeks) , .

Techniques: Isolation, Picogreen Assay, Multiplex Assay, Software